Amarin Corp Plcuk (AMRN) Amortization of Deferred Charges (2012 - 2020)
Amarin Corp Plcuk (AMRN) reported Amortization of Deferred Charges of $34000.0 for Q4 2020, down 90.61% year-over-year from $362000.0 in Q1 2020, and down 69.37% quarter-over-quarter from $111000.0 in Q3 2020.
Amarin Corp Plcuk (AMRN) Amortization of Deferred Charges (2012 - 2020) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 9 years of Amortization of Deferred Charges data on file, last reported at $34000.0 in Q4 2020.
- Amortization of Deferred Charges for Q4 2020 came in at $34000.0, down 90.61% year-over-year; the trailing twelve-month figure through Dec 2020 was $635000.0 (down 61.37% YoY), and the FY2020 annual result was $635000.0, down 61.37% from the prior year.
- Amortization of Deferred Charges slipped to $34000.0 in Q4 2020 per AMRN's latest filing, from $111000.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $2.6 million in Q2 2016 and troughed at $34000.0 in Q4 2020.
- A 5-year average of $728850.0 and a median of $542000.0 in 2016 frame the typical range for Amortization of Deferred Charges.
- The sharpest annual moves came in 2016 and 2020: Amortization of Deferred Charges soared 36.65% in 2016, then sank 90.61% in 2020.
- A 5-year view of Amortization of Deferred Charges shows it stood at $537000.0 in 2016, then advanced by 10.99% to $596000.0 in 2017, then fell by 16.78% to $496000.0 in 2018, then retreated by 27.02% to $362000.0 in 2019, then slumped by 90.61% to $34000.0 in 2020.
- Business Quant data shows AMRN's Amortization of Deferred Charges at $34000.0 in Q4 2020, $111000.0 in Q3 2020, and $201000.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 34,000.00 |
| Dec 31, 2020 | 34,000.00 |
| Sep 30, 2020 | 111,000.00 |
| Sep 30, 2020 | 111,000.00 |
| Jun 30, 2020 | 201,000.00 |
| Jun 30, 2020 | 201,000.00 |
| Mar 31, 2020 | 289,000.00 |
| Mar 31, 2020 | 289,000.00 |
| Dec 31, 2019 | 362,000.00 |
| Dec 31, 2019 | 362,000.00 |
| Sep 30, 2019 | 404,000.00 |
| Sep 30, 2019 | 404,000.00 |
| Jun 30, 2019 | 432,000.00 |
| Jun 30, 2019 | 432,000.00 |
| Mar 31, 2019 | 446,000.00 |
| Mar 31, 2019 | 446,000.00 |
| Dec 31, 2018 | 496,000.00 |
| Dec 31, 2018 | 496,000.00 |
| Sep 30, 2018 | 547,000.00 |
| Sep 30, 2018 | 547,000.00 |